Advertisement

Topics

Search Results for "Where To Buy Pirfenidone"

02:12 EST 6th February 2016 | BioPortfolio

Matching Channels

None

Matching News

Boehringer begins trial to assess OFEV with pirfenidone in IPF patients

Germany's Boehringer Ingelheim has started a new 12-week multinational trial to evaluate the safety, tolerability and pharmacokinetics (PK) of add-on treatment with pirfenidone to background therapy w...

Trial of Ofev and pirfenidone in IPF starts

Initiation of first multinational study to evaluate safety of OFEV® (nintedanib) with add-on of pirfenidone in patients with IPF

Antifibrotic Agent Cuts Mortality in IPF (CME/CE)

(MedPage Today) -- Pooled data show significant reduction with pirfenidone

Genentech exploring IPF as positive new Esbriet mortality data announced

New data has shown Esbriet (pirfenidone) from Roche’s Genentech unit can reduce risk of death in idiopathic…

Pharmacologic Treatment of Idiopathic Pulmonary Fibrosis

What questions remain about the recently approved medications for the treatment of idiopathic pulmonary fibrosis -- pirfenidone and nintedanib. Current Opinion in Pulmonary Medicine

New Roche Esbriet data show clinical benefits of continued and long-term treatment in patients with idiopathic pulmonary fibrosis (IPF)

Roche today announced that new clinical data and abstracts on Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF) are being presented at the European Respiratory Society (ERS...

New data will be presented for Roche's Esbriet in idiopathic pulmonary fibrosis at European Respiratory Society Congress 2015

Roche today announced that new Esbriet (pirfenidone) data analyses in idiopathic pulmonary fibrosis (IPF) will be presented at the European Respiratory Society (ERS) congress in Amsterdam, 26-30 Septe...

Matching PubMed Articles

Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.

A phase III clinical trial of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) in Japan has revealed that pirfenidone attenuated the decline in vital capacity (VC) and improved progres...

All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease with a median survival of 2-5 years and limited treatment options. In 2008, pirfenidone became the first drug to be approved for ...

Therapeutic advances in Idiopathic Pulmonary Fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a primary lung disorder that scars distal airspaces and has a prognosis similar to many aggressive cancers. After decades of failed clinical trials, two drugs (n...

Idiopathic pulmonary fibrosis: the turning point is now!

treatment options, which now have become available for patients. In face of the newly available therapies we present an update on the pathophysiology and epidemiology of IPF. We discuss the typical cl...

Risk factors for acute exacerbation of idiopathic pulmonary fibrosis - Extended analysis of pirfenidone trial in Japan.

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a lifethreatening event and one of the important endpoints in clinical trials involving IPF. Despite this, there has been little evaluat...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement